Fluorescence tumor imaging using exogenous fluorescent tumor-targeting agents has potential to improve early tumor detection. The fluorescent contrast agent indocyanine green (ICG) is used in medical diagnostics. The aim of the present study is to investigate the tumor imaging capability and the imaging mechanism of i.v. Abbreviations: AOM, azoxymethane; CCD, charge-coupled device; DSS, dextran sodium sulfate; HO-1, heme oxygenase-1; ICG, indocyanine green; iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; NTCP, sodium-taurocholate co-transporting polypeptide; PGE2, prostaglandin E2; TL488, Lycopersicon esculentum (tomato) lectin conjugated with DyLight 488.
| INTRODUCTION
Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, is a risk factor for the development of colitis-associated colorectal cancer. [1] [2] [3] It is difficult to detect colitis-associated colorectal cancer using white-light colonoscopy because of the background mucosal changes associated with long-term colitis and morphological diversity of the cancer. 4 Therefore, for screening colonoscopy to detect dysplasia or early stage cancer, four random biopsies every 10 cm of the whole colorectal tissue using white-light endoscopy has traditionally been recommended. 4 However, this approach is quite cumbersome and time consuming. Therefore, the development of detection techniques that provide biological information with sufficient sensitivity and specificity is necessary to improve the current situation.
Fluorescence tumor imaging using exogenous fluorescent tumortargeting agents has been investigated for applications in endoscopy. [5] [6] [7] In this technique, neoplastic lesions are visually enhanced with specific biomarkers targeted by the fluorescent agents. The advantages of fluorescence tumor imaging include its high specificity and sensitivity, real-time video frame-rate imaging, relatively low cost, portability, and the absence of radiation exposure. 8, 9 It may, therefore, be a valuable method in early cancer detection. However, despite the variety of tumor imaging agents developed thus far, many of those intended for use in humans are still in preclinical or early phase clinical trials. 6 Indocyanine green is a fluorescent contrast agent approved for clinical applications in the USA and some European and Asian countries, including Japan. Because i.v. administered ICG is excreted exclusively by the liver, it has been used for decades to assess hepatic function in humans and has an excellent safety profile. 10 Recently, tumor accumulation of ICG has been reported in a variety of tumor types, including tumors of the liver, 11, 12 breast, 13 head and neck, 14 and lungs 15 in humans. Detection of tumor metastatic lesions using ICG has also been reported in ovaries 16 and colon. [17] [18] [19] [20] However, the mechanism allowing tumor detection by ICG is poorly understood.
Currently, there are three potential mechanisms of ICG-based tumor imaging. In hepatic tumors, ICG positivity is partly correlated with influx transporters, organic anion transporting polypeptide 1B3
and NTCP, 21, 22 both of which are normally expressed in hepatocytes and mediate the cellular uptake of ICG in vitro. 23 In experimental tumor models of the colon, endocytosis associated with tight junction disruption of the epithelial cells has been shown to increase ICG uptake capability. 24, 25 In other cases, ICG-based tumor imaging is thought to be caused by the enhanced permeability and retention effect of the nano-sized ICG-plasma protein complex. 26 Indocyanine green fluorescence signal intensity in the tumor tissues correlates with microvascular density, 27 which is one of the parameters affecting the enhanced permeability and retention effect. Revealing the tumor imaging mechanism of ICG supports the precise clinical usage of ICG in tumor detection.
The aim of this study is to investigate the tumor imaging capability and the imaging mechanism of i.v. administered ICG in a mouse model of colitis-associated colon cancer. To do this, we examined the imaging capability of ICG using ex vivo wide-field imaging in an AOM/DSS-induced colon carcinogenesis model. We further investigated the mechanism underlying tumor tissue uptake of ICG using ex vivo microscopic imaging, immunofluorescence analysis, and cultured cell experiments.
| MATERIALS AND METHODS

| Fluorescent agents
Pharmaceutical grade ICG was purchased from Daiichi-Sankyo (Diagnogreen; Tokyo, Japan). Blood vessels were visualized using TL488 (Vector Laboratories, Burlingame, CA, USA).
| Fluorescence imaging systems
The basic specifications of fluorescence imaging systems has been reported previously. 24 Briefly, macroscopic images were captured using a fluorescence reflectance imaging system (OV100; Olympus, Tokyo, Japan) equipped with a 150 W xenon light source and a color digital CCD camera (DP71; Olympus). Excitation and emission filters for ICG fluorescence imaging were 730 AE 22.5-nm band-pass and 770-nm long-pass filter, respectively. High-power view was observed using a multi-wavelength laser scanning microscope (IV100; Olympus)
equipped with a 748-nm diode laser with 17 mW power output and a photomultiplier tube. The emission filter to detect ICG fluorescence was a 779-nm long-pass filter. Tissue sections were scanned using a fluorescence virtual microscopy system (VS120-FL; Olympus) equipped with a 200 W mercury light source (X-Cite exacte; Excelitas Technologies, Waltham, MA, USA) and a monochrome digital CCD camera (ORCA-R2; Hamamatsu Photonics, Hamamatsu, Japan). Excitation and emission filters for ICG fluorescence were 708 AE 37.5-nm band-pass and 809 AE 40.5-nm band-pass filter, respectively. Fluorescence images are shown in grayscale or pseudo-colors.
| Experimental tumor model
The AOM/DSS-induced colitis-associated colon cancer mouse model was constructed according to the methods described previously, [28] [29] [30] with some modifications. The 38 female ICR mice (4 weeks old) used in this study were purchased from Japan SLC (Shizuoka, Tokyo). 
| Ex vivo imaging
Imaging experiments were carried out 4-6, 10-12, and 18-20 weeks after injection of AOM (n = 10-11 for each time period). The AOM/ DSS-treated mice (n = 5 for 4-6 weeks, n = 6 for 10-12 weeks, and n = 9 for 18-20 weeks) were i.v. injected with 100 lL (7.5 mg/kg) ICG 24 and left untreated for 1 hour. The blood circulation time of ICG was determined based on the results of preliminary experiments of ex vivo colon tumor imaging at different exposure time points (n = 1 each for 30 minutes and 6 hours at the time period of 4-6 weeks; Figure S1 ). The AOM/DSS-treated mice without ICG injection were also prepared (n = 3 for 4-6 weeks and 10-12 weeks, and n = 1 for 18-20 weeks). The AOM/DSS-untreated control mice were injected with ICG (n = 3 for 4-6 and n = 3 for 18-20 weeks). In these animals, TL488 was i.v. injected at 100 lg/100 lL per mouse 10 minutes before they were killed by exsanguination under isoflurane anesthesia. The excised colon tissues were cut to reveal the intestinal mucosa, washed with PBS (pH 7.4), and then subjected to ex vivo imaging. As a control, colon tissues from AOM/DSS-treated mice without ICG administration or normal mice with ICG administration were used. A preliminary experiment with an ICG enema was also undertaken, as previously reported. 25 The AOM/DSS-treated mice (n = 1 each for 4-6 and 10-12 weeks) were given 500 lL ICG at 30 lg/mL by enema and then subjected to imaging analysis as described above.
| Histology and immunofluorescence
In all animals, the excised colon tissues used in the histopathological examination were fixed overnight in phosphate-buffered 10% formalin (pH 7.4). Paraffin-embedded tissue sections stained with H&E were used to diagnose the proliferative lesions in the mouse colon.
The proliferative lesions were histopathologically classified as dysplasia, adenoma, and adenocarcinoma. 30, 31 Immunofluorescence was carried out using methanol-fixed snap-frozen sections of colon tissues obtained from the mice 18-20 weeks after their i.p. injection of AOM. The sections were incubated with primary antibodies (Table S1 ) overnight at 4°C, and then with species-appropriate antibodies labeled with Alexa Fluor 488 or 594 (Thermo Fisher Scientific, Waltham, MA, USA) for 1 hour at room temperature, and counterstained with DAPI (Thermo Fisher Scientific).
| In vivo vascular permeability assay
In vivo vascular permeability was measured as reported previously, 32 with some modifications. Prostaglandin E 2 (2 lg/20 lL/ear) was intradermally injected to the right ear of the normal nude mice (n = 4). As a control, the same amount of PBS was injected to the left ear. Fifteen minutes after PGE 2 injection, ICG (7.5 mg/kg body weight) was given i.v. One minute after ICG injection, macroscopic imaging using OV100
was carried out to detect vascularity of the ears. Approximately 10-12 min after ICG injection, ICG accumulation in the ear was observed by IV100. Fluorescence signals were measured using OV100 or IV100 software.
| Statistical analysis
Fluorescence images were analyzed using ImageJ software (NIH, Bethesda, MD, USA). The mean fluorescence intensity of ICG in colon tissues was measured and then the tumor to normal tissue ratio was calculated. Numerical data are presented as the mean AE SD. Numerical data of the in vivo study, consisting of more than three sample groups, were assessed using Tukey-Kra- Figure S1 ), whereas autofluorescence was rarely observed in ICG non-administered AOM/DSS-treated mice ( Figure 1A , Figure S1 ). proliferative lesions in AOM/DSS-treated mice was significantly higher than that of colon tissues in normal mice or non-tumor tissues in AOM/DSS-treated mice ( Figure 1B , Figure S1 ). In AOM/ DSS-treated mice, the tumor to normal tissue ratio was >2 and significantly higher than that of the ICG non-administered group in each time period ( Figure 1C ). 
|
| Microscopic analysis of ICG fluorescence localization in the colon tumor tissues
Ex vivo microscopic imaging revealed that blood vessels in the tumor tissues showed distorted and thick vasculatures compared with normal mucosal blood vessels ( Figure 3A ). In the tumor tissues, ICG fluorescence was distributed in the stromal tissues around the blood vessels in each time period ( Figure 3A , Figure S1 ).
The ICG fluorescence was unevenly distributed in the mucosa and not in the muscle layer ( Figure 3A ). Indocyanine green fluorescence was not observed in the tumor parenchyma in any time period (Figures 3A, Figures S1) . The tumor to normal tissue ratio of ICG fluorescence in mice 10-12 or 18-20 weeks after injection of AOM was significantly higher than that in the ICG non-administered group ( Figure 3B ).
| Vascular component analysis in colon tumor tissues
The area of CD31 + endothelial cells in the tumor tissues was larger and thicker than that of normal colon tissues ( Figure 4A ). CD31 
| Vascular permeability in colon tumor tissues
Vascular permeability is known to be promoted by inflammatory mediators, such as COX-2, iNOS, and HO-1. 33 Immunoreactivity of COX-2 was observed in stromal cells in the colon tissues ( Figure 5A ). The COX- Figure 5A ,B and Figure S4 ).
In the endothelial cell permeability assay using an HH cell monolayer (Document S1), ICG passed through the membrane without the monolayer, whereas ICG reduced permeability through the non-trea- Figure S5 ).
In the in vivo vascular permeability assay, ICG fluorescence was significantly increased in the ear after intradermal injection of PGE 2 compared with ears injected with PBS ( Figure 5C-F ).
| Expression of tight junction and transporter molecules in colon tumor tissues
The localization of occludin at the apical cell border was observed both in the tumor tissues of AOM/DSS-treated mice and normal colon epithelium of untreated control mice or AOM/DSS-treated mice, whereas immunoreactivity of occludin in the tumor cell cytoplasm was increased compared with the normal colon epithelium ( Figure 6A ). Zonula occludens-1 was expressed at the apical cell border both in the normal tissues and tumor tissues.
The immunoreactivity of zonula occludens-1 in the tumor cells was not changed from normal colon epithelium ( Figure 6A ).
Immunoreactivity of NTCP was observed at the cell surface membrane both in the tumor cells and normal colon epithelial cells ( Figure 6B ). In the ICG enema experiment using AOM/DSStreated mice, ICG did not accumulate in the tumor tissues ( Figure S6 ). relates with microvascular density. 27 These results suggested that ICG accumulation in the tumor tissues was likely promoted by increasing tumor vascularity, leading to an increase in the chance for ICG to extravasate from tumor blood vessels.
| DISCUSSION
In the present study, ICG fluorescence was distributed in the stromal tissues around the tumor blood vessels, whereas only weak ICG fluorescence was observed in the normal colon stromal tissues.
Therefore, it can be postulated that blood vessel permeability of ICG plays a major role in ICG accumulation in the tumor tissues. It is known that extravasation of i.v. administered agents from blood vessels is promoted by the absence of pericytes. 34 However, in the present study, endothelial cells covered with/without a-smooth muscle actin-positive pericytes were observed in both normal colon tissues and colon tumor tissues. Therefore, these results suggest a minor role of the lack of pericyte coverage of endothelial cells in ICG-mediated tumor enhancement in the current model. However, vascular permeability is also known to be promoted by inflammatory mediators, such as COX-2, iNOS, and HO-1. 33 In our study, strong immunoreactivities of COX-2, iNOS, and HO-1 were observed in the AOM/DSS-induced tumor colon tissues, similar to previous studies. 35 accumulation capability of agents to the tumor tissues may be affected by impaired lymphatic drainage, which enhances agent retention in the tumor tissues, and enhanced vascular permeability, which promotes agent delivery to the tumor tissues. 38 Therefore, future work will be needed to clarify the contribution of the retention effect on ICG-based tumor imaging.
In the AOM/DSS-induced tumor tissues in the present study, tumor cells did not take up ICG, whereas ICG was distributed in the stromal tissues around the tumor parenchyma. Furthermore, ICG did not accumulate in the tumor tissues, even in the ICG enema experiment, in contrast to ICG accumulation by ICG enema in AOM-induced colon tumor tissues using rats in our previous study. 25 In our previous study using a mouse xenograft model of human colon cancer cells, we revealed that cellular uptake of ICG is mediated by endocytosis in association with disruption of tight junctions. 24 In another study using rats, as mentioned above, we also reported altered expression of occludin, which could lead to disruption of tight junctions and further endocytosis of ICG, in parallel with tumor cellular uptake of ICG. 25 
